CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 14, 2024

Primary Completion Date

December 18, 2025

Study Completion Date

June 18, 2026

Conditions
B-Cell Lymphoblastic Leukemia/Lymphoma
Interventions
DRUG

CD19&CD20 bispecific CAR-T cells

Each patient will receive CD19\&CD20 bispecificCAR-T cells by intravenous infusion on day 0.

Trial Locations (1)

430022

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

collaborator

Zhujiang Hospital

OTHER

collaborator

Jingzhou Central Hospital

OTHER

collaborator

Shiyan People's Hospital

UNKNOWN

collaborator

Xiangyang Central Hospital

OTHER

collaborator

Yichang Central People's Hospital

OTHER

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER